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’INTRODUCTION
Genetic information is encoded in DNA by the speciﬁc linear
sequenceofitsbases.Theexpressionofthisinformationisregulated
by protein scaﬀolds that are capable of reading the complex code of
post-translational modiﬁcations that occur on chromatin. Acetyla-
tion of histones lysine residues is one such essential component in
the epigenetic regulation of gene expression.
1 Additionally, recent
proteomicsstudieshavedemonstratedthatlysineacetylationoccurs
in over 1750 cellular proteins involved in diverse roles such as cell
cycle, splicing, nuclear transport, and actin nucleation.
2 Lysine
acetylationonhistonesandotherproteinsiseﬀectedbythedynamic
interplay of acetyltransferase (HAT) and deacetylase (HDAC)
enzymes, which is analogous to the regulation of serine, threo-
nine, and tyrosine phosphorylation by kinases and phosphatases.
Bromodomains are a family of conserved ∼110 amino acid
modules that bind selectively to acetylated lysines present in
proteins, notably histones,
3 and are thereby thought to partici-
pate indeciphering thehistonecode.
4Bromodomains have been
classiﬁed into several distinct subgroups according to the func-
tionoftheirparentprotein:(i)histoneacetyltransferases(HATs),
including CREBBP, GCN5, PCAF, and TAFII250; (ii) in com-
ponents of ATP-dependent chromatin-remodeling complexes
such as Swi2/Snf2; and (iii) the BET (bromodomain and extra
C-terminal domain) family, a class of transcriptional regulators
carrying tandem bromodomains and an extra terminal domain.
5
Although the biological roles of most bromodomains in the
human genome remain elusive, those that have been character-
ized are fundamental. For example, the BET bromodomain-
containing protein (BRD) 4 plays a key role in several cellular
processes, including mitosis.
6 Expression levels of BRD4 corre-
latewithbreastcancersurvivalrates,
7andinasubsetofmalignant
squamous carcinomas, the N-terminal bromodomains of BRD4
arefusedinframetotheNUTgenegivingrisetoextremelyaggres-
sive tumor growth.
8 Knockdown experiments have implicated
BRD4 in the transcriptional regulation of viruses such as HIV
9
and EBV,
10 as well as the degradation of HPV.
11 BRD4 was also
shown to be required for transcriptional coactivation of NF-kB,
regulating the transcription of P-TEFb-dependent pro-inﬂam-
matory target genes.
12 A second BET-family protein, the testis-
speciﬁc BRDT, is essential for male germ cell diﬀerentiation in
selective domain knockout mice that were viable but sterile.
13
The development of small molecule inhibitors of bromodo-
mainbindingtohistonesandotheracetyl-lysine-containingproteins
is in its infancy. Weakly potent small molecule ligands of the
cAMP response element-binding protein (CREB) binding pro-
tein(CREBBP)bromodomain,discoveredbyNMRscreeningof
acetyl-lysine (KAc) mimics, have been shown to modulate p53
Received: May 19, 2011
ABSTRACT: Histone lysine acetylation is a vital chromatin post-
translational modiﬁcation involved in the epigenetic regulation of gene
transcription. Bromodomains bind acetylated lysines, acting as readers
of the histone-acetylation code. Competitive inhibitors of this interac-
tion have antiproliferative and anti-inﬂammatory properties. With 57
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stability and function in response to DNA damage in cells.
14
More recently, a 4-hydroxyphenylazobenzenesulfonic acid deri-
vative was shown to bind to the CREBBP bromodomain, with
KD =1 9μM, and consequently blocks p53-dependent apoptosis
in cardiomyocytes under DNA-damage stress.
15
Ligands have also been developed for the BET family of bromo-
domains. A benzimidazole-derived BRD2(1) ligand with KD =2 8
μM reduced the transcription of BRD2-dependent genes.
16 Anti-
proliferativeeﬀectsagainstanumberofcelllineshavebeenclaimedin
a patent for a series of thienotriazolodiazepine BRD2/3/4 blockers
with nanomolar in vitro peptide displacement activity.
17 The structu-
rally related (+)-JQ1 (Figure 1A), recently characterized as a
BET-family selective chemical probe, shows speciﬁc antiproli-
ferative eﬀects in BRD4-dependent cell lines and patient-derived
xenograft models.
18 In addition, a recently identiﬁed BET bromo-
domain blocker (I-BET, Figure 1B) suppressed lipopolysaccharide-
inducible genes in macrophages and showed anti-inﬂammatory
eﬀectsinmice.
19Thisworkdemonstratesthefeasibilityofinhibiting
KAc binding to bromodomains with small molecules that occupy
thewell-deﬁnedKAc-bindingpocket.Itispossiblethattargetingthis
pocket might prove more tractable than developing inhibitors of
catalytic activity in certain enzymes. In addition, small molecule
inhibitionofbromodomain proteininteractionsmightelicitsubtly
diﬀerentpharmacologicalresponsestotheinhibitionofthecatalytic
domain of the same protein.
20
The ﬁndings outlined above demonstrate clearly the need for
systematic generation of high aﬃnity subfamily selective bromo-
domain-binding small molecules that can be used as chemical
probes to explore further the roles of individual bromodomains.
Thesemoleculeswillprovidecomplementarydatatostudiesusing
knockdown, peptide and antibody approaches, and will enable
prediction of the likely phenotypes of eventual small molecule
drugs. As part of our ongoing goal to generate cell-penetrant
chemicalprobesforbromodomains,wehavepreviouslydeveloped
bromodomain histone peptide binding assays to allow the iden-
tiﬁcation of fragment and small molecule ligands.
21 Herein, we
describe the use of these assays, together with a structure-based
design approach, to identify and develop the structure activity
relationships (SAR) of a novel series of 3,5-dimethylisoxazole-
containing bromodomain histone binding inhibitors.
We demonstrate that the 3,5-dimethylisoxazole moiety is an
eﬀectiveKAcmimicandshowhowdiﬀerentialsubstitutionofthe
3,5-dimethylisoxazole core gives derivatives that bind with some
selectivity and useful aﬃnity to either the ﬁrst bromodomain of
humanBRD4[BRD4(1)]orthebromodomainofhumanCREBBP.
’RESULTS AND DISCUSSION
In the course of our work, we discovered that the solvent
N-methyl pyrrolidinone (NMP) interacts with the KAc-binding
pocket of a range of bromodomains, showing weak aﬃnity but,
because of its low molecular weight, high ligand eﬃciency
(0.30 0.53, see Supporting Information, Table S1), with IC50
values ranging from 34 mM for the bromodomain adjacent to
zinc ﬁnger domain 2B (BAZ2B) to 2.3 mM for CREBBP.
21
During subsequent studies on methyl-bearing heterocycles, we
purchased and tested the dihydroquinazolinone-containing 3,
5-dimethylisoxazolederivative1(Figure1C)andobservedunex-
pectedly low IC50 values of ∼3 μM against the ﬁrst bromodo-
mainofBRD2[BRD2(1)] and∼7μMagainstBRD4(1).Docking
studies suggested that two binding modes were possible for this
compound,witheitherthedihydroquinazolinoneor3,5-dimethyl-
isoxazole moiety acting as a KAc bioisostere (data not shown).
To explore the possibility that the 3,5-dimethylisoxazole might
occupy the KAc-binding pocket, we obtained an X-ray crystal
structure of the complex between human BRD4(1) and 1.
The X-ray crystal structure of the BRD4(1) complex was
solved at 1.98 Å (Figure 2A, PDB ID: 3SVF). It demonstrated
that the 3,5-dimethylisoxazole was indeed acting as a KAc
bioisostere, accepting a hydrogen bond from the conserved N
residue within the binding pocket [N140 in BRD4(1)], which
mimics the key interaction made with the carbonyl oxygen of
KAc. Additionally, we observed additional unexplained electron
density at the 4-position of the dihydroquinazolinone that was
interpretedasasubstitutionofonehydrogenatombyanethylene
glycol unit (Figure 2B). As dihydroquinazolinones are liable to
benzylicoxidationunderlaboratoryconditions(SupportingInfor-
mation, Figure S1),
22 we hypothesized that this product 2 might
arise from oxidation at this position to form the corresponding
iminium species, followed by the addition of ethylene glycol,
Figure1. (A)StructureoftheBETprobe(+)-JQ1.
18(B)StructureoftheBETprobeI-BET.
19a(C)Structureofdihydroquinazolinone-containing3,5-
dimethylisoxazole derivative 1. (D) The concept employed in the design of the 3,5-dimethylisoxazole-based bromodomain inhibitors.6763 dx.doi.org/10.1021/jm200640v |J. Med. Chem. 2011, 54, 6761–6770
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which is present in the crystallization buﬀer (see Supporting
Information, Figure S1 for mass spectrometry analysis). Inter-
estingly, only one enantiomer was observed in the X-ray crystal
structure; the ethylene glycol unit attached to the stereogenic
center occupies a hydrophobic groove formed by W81 and P82
from the ZA loop and I146 and M149 from helix C. Occupation
of this site by the 4-chlorophenyl substituent of (+)-JQ1 and
I-BET(Figure1A,B)isbelievedtocontributetotheselectivityof
the these compounds for the BET subfamily over other bromo-
domains since a similar groove is not available in other bromo-
domains(Figure2C).
18Inaddition,weobservedthatasampleof
1 displayed signiﬁcant cytotoxicity in the HeLa human cell line,
while (+)-JQ1 showed no cytotoxicity over the same concentra-
tion range (Supporting Information, Figure S2). Therefore, the
development of analogues that do not possess a readily oxidized
benzylic methylene unit, but that could form interactions with
this groove, was pursued. The mono- and di-meta-substituted 3,
5-dimethyl-4-phenylisoxazole scaﬀolds (3a d and 4a d)w e r e
chosentoallowextensionfromthearomaticcoreintwodirections
(Figure 1B). Initial docking studies suggested that a single meta-
substituentwouldoccupyapositionsimilartothatoftheethylene
glycolmoietyof 2(Supporting Information, Figure S3A). Asecond
meta-substituent would be directed into a groove (referred to by
Nicodeme et al.
19a and Chung et al.
19b as the ZA channel) deﬁned
byW81ononesideandL92ontheother(SupportingInformation,
Figure S3A). Consequently, the 3,5-dimethylisoxazole derivatives
3a d and 4a d were selected as target molecules that contain
a range of substituents to enable exploration of the KAc-binding
pocket of the bromodomains.
Thesynthesesof3a dand4a dareshowninSchemes1 3.
Initial work focused on the direct arylation of 3,5-dimethylisox-
azoleusingPd-catalyzedC Hbondactivation.
23Whilethisreaction
proceeded well with bromobenzene 5, lower yields were obtained
onreactionwith6and10(SupportingInformation,SchemeS1).
Furthermore,thereaction hasbeenreportedtobelesssuccessful
with electron-rich aryl bromides.
23 Conversely, Molander et al.
have demonstrated that potassium heteroaryltriﬂuoroborates
react eﬃciently with both electron-rich and electron-deﬁcient
arylhalides,withlowcatalystloadingsandminimalprotodeboro-
nation.
24 Therefore, we prepared potassium (3,5-dimethylisox-
azol-4-yl)triﬂuoroborate 8from (3,5-dimethylisoxazol-4-yl)boronic
acid.
24 Coupling of 8 to commercially available aryl bromides 5
and6,andarylbromide7(easilypreparedfrom3-bromophenol,
25
Supporting Information, Scheme S2) aﬀorded 3,5-dimethyl-
4-phenylisoxazole 3a and the 30-substituted 3,5-dimethyl-4-phe-
nylisoxazoles3band3cinexcellent yields (Scheme1).Although
the coupling reactions did proceed when conducted with (3,5-
dimethylisoxazol-4-yl)boronic acid (data not shown), the yields
observed were lower than those in the route described above.
The30,50-disubstituted3,5-dimethyl-4-phenylisoxazoles4a c
wereprepared from3-bromo-5-hydroxybenzoicacid9(Scheme2).
Alkylation of 9 aﬀorded the ethyl ester 10, which was coupled to
8, yielding 4a. Subsequent LiOH-mediated hydrolysis furnished
the carboxylic acid 4b. Alternatively, the ethyl ester of 10 was
converted to the acetyl group via the Weinreb amide 12 in three
steps;coupling,underthesameconditionsemployedabove,yielded
the isoxazole 4c.T h em e t h y lk e t o n e s3b and 4c were converted to
the racemic secondary alcohols 3d and 4d by reduction of the
ketone with NaBH4 (Scheme 3).
Figure2. (A)TheX-raycrystalstructureof2(carbon=yellow,PDBID,3SVF)boundtohumanBRD4(1).TheconservedN140residueishighlighted
ingreen.(B)2Fo Fcmapat2σoftheobservedligand2.(C)Overlayofcrystalstructures of2(carbon=yellow)and(+)-JQ1(carbon=orange,PDB
ID: 3MXF) bound to human BRD4(1), showing that the ethylene glycol unit binds in the same region as the chlorophenyl moiety of (+)-JQ1. The
images were generated and structure alignment conducted using PyMOL.
Scheme 1. Synthesis of the 30-Substituted 3,5-Dimethyl-
4-phenylisoxazole Derivatives 3a c
a
aConditions:(a)R=H:Na2CO3,Pd(OAc)2,RuPhos,EtOH,85C,4h,
85%. R = Ac: Na2CO3, Pd(OAc)2, RuPhos, EtOH, 85 C, 13 h, 86%.
R = OEt: Na2CO3, Pd(OAc)2, RuPhos, EtOH, 85 C, 2 h, 87%.6764 dx.doi.org/10.1021/jm200640v |J. Med. Chem. 2011, 54, 6761–6770
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To enable accurate comparison with our new compounds, a
sampleof1wasresynthesized(SupportingInformation,SchemeS3).
Biological evaluation of 1 was conducted using freshly prepared
DMSO solutions to minimize the possibility of oxidation (see
Supporting Information for details).
To determine whether the compounds inhibited bromodo-
main histone binding, we utilized a peptide displacement
assay based on AlphaScreen technology.
21 For the ﬁrst bromo-
domain of BRD2 [BRD2(1)] and BRD4(1), a histone H4
peptide acetylated at K5, 8, 12, and 16 was employed, while
for CREBBP an H3 peptide acetylated at K56 was used. IC50
values for compounds 1, 3a d,a n d4a d a r es h o w ni nT a b l e1
(dose response curves for 1, compounds 4b and 4d in BRD4(1),
BRD2(1), and CREBBP are shown in Supporting Information,
Figure S4). With the exception of 3a, all compounds inhibited
BRD4(1) and BRD2(1) with IC50 e 50 μM, the most potent
compoundsshowing low micromolaractivity.Introduction ofan
ethoxy substituent at R
2 increases potency against BRD4(1) and
BRD2(1). A variety of substituents at R
1 are well tolerated, with
the exception of R
1 =C O 2H in which the positioning of a
negatively charged substituent in a hydrophobic site is likely to
disfavor binding. IC50 values were generally higher against
CREBBP, except for 4b (R
1 =C O 2H) where the IC50 for
CREBBP was lower than that for BRD4(1) and similar to
that for BRD2(1). Gratifyingly, 4b and 4d did not show
any cytotoxicity in a human cell line (Supporting Information,
Figure S2).
To investigate the selectivity of these compounds against
other bromodomains, we employed a binding assay based on
proteinstabilityshift(Table2).
26Ofthecompoundsthatproduced
substantial changes in melting temperature (ΔTm
obs), most dis-
played selectivity for BET bromodomains. However, 4b d also
produce an appreciable ΔTm
obs with CREBBP, in agreement with
the IC50 values. Indeed, 4b showed selectivity, albeit modest, for
CREBBP over the BET bromodomains.
In order to conﬁrm that the dimethylisoxazole moiety was acting
as a KAc mimic and to elucidate structure activity proﬁles for
Scheme 2. Synthesis of the 30,50-Substituted 3,5-Dimethyl-
4-phenylisoxazole Derivatives 4a c
a
aConditions: (a) EtBr, K2CO3, DMF, 100 C (microwave), 15 min,
96%; (b) 8,N a 2CO3, Pd(OAc)2, RuPhos, EtOH, 100 C, 48 h, 70%;
(c) LiOH, THF, H2O, rt, 16 h, 83%; (d) LiOH, THF, H2O, rt, 23 h,
95%; (e) NHMe(OMe)3HCl, HBTU,
iPr2NEt, DMF, rt, 14 h, 80%;
(f) MeMgBr, THF, rt, 15 h, 86%; (g) 8,N a 2CO3, Pd(OAc)2, RuPhos,
EtOH, 85 C, 64 h, 67%.
Scheme 3. Synthesis of the Secondary Alcohols 3d and 4d
a
aConditions: (a) NaBH4, MeOH, rt, 2 h, R = H: 77%. R = OEt: 81%.
Table 1. Eﬀect of 30- and 50-Substituents on Competitive
Displacement of Histone Peptides from the BRD4(1) and
BRD2(1), and CREBBP Bromodomain
a
aProtein and peptide concentration: 50 nM. Protein and peptide
concentration: 100 nM. Heat map shows relative IC50 values; red
indicates low IC50 values, and green indicates high IC50 values. Ranges
in parentheses represent 95% conﬁdence intervals resulting from
sigmoidal curve ﬁtting to duplicate data. n.d. = not determined.6765 dx.doi.org/10.1021/jm200640v |J. Med. Chem. 2011, 54, 6761–6770
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these compounds, we obtained cocrystal structures of BRD4(1)
with 4d and the CREBBP bromodomain with 4b (Figures 3
and 4).
Thecostructureof4dboundtoBRD4(1)wasobtainedat1.68Å
resolution(PDBID:3SVG).Globally,theligand-boundandapo
structures (PDB ID: 2OSS) are very similar, with a rmsd of 0.17.
Thisstructure conﬁrms that 4d binds with thedimethylisoxazole
oriented into the KAc-binding pocket as anticipated by our
docking studies (Supporting Information, Figure S3B). It is
predicted that the isoxazole oxygen atom forms the expected
hydrogen bond with the amine group of the conserved N140
(green, Figure 3A). The isoxazole nitrogen atom interacts with
the phenol group of Y97 via the structured water molecule A
(Figure 3B).
Although 4d was synthesized as a racemate, the electron density
for this compound implies that the (R)-enantiomer crystallizes
preferentiallywithBRD4(1).Thesecondaryalcoholformsanetwork
of hydrogen bonds with water molecules B E, which interact
with D144, D145, and the carbonyl oxygen atom of N140. The
methyl group attached to the secondary alcohol binds within the
hydrophobic pocket (pocket 2, Figure 3B) that is deﬁned by
I146, M149, and W81, the latter forming part of the WPF shelf
(described by Nicodeme et al. as W81, P82, and F83).
19a This
is the same pocket that binds the ethylene glycol unit of 2
(Supporting Information, Figure S3C) and the chlorophenyl
moieties of I-BET and (+)-JQ1 (Supporting Information, Figure
S3D). The ethyl ether binds within the ZA channel (pocket 3,
Figure3B)thataccommodatesthethiophenemoietyof(+)-JQ1
and the methylated phenol of I-BET. Therefore, analysis of the
X-ray crystal structure of 4d in complex with BRD4(1) shows
that this compound is forming interactions in many of the same
regions as (+)-JQ1 and I-BET, perhaps explaining how a
compoundwithrelativelylowmolecularweight(261)stillshows
goodaﬃnityforBRD4(1)andreasonableselectivityfortheBET
subfamilyofbromodomains.Indeed,4dhasligandeﬃcienciesof
0.39 for BRD4(1) and 0.43 for BRD2(1), which compare
favorably with the value of 0.32 for (+)-JQ1 at BRD4(1) (see
Supporting Information, Table S1 for details of ligand eﬃciency
calculations).Theseligandeﬃcienciessuggestthatcompound4d
is a promising lead for the development of BET bromodomain
Table 2. ΔTm
obs against Selected Bromodomains
a
aCompound concentration, 100 μM; protein concentration, 2 μM. Heat map shows relative ΔTm
obs; red indicates large ΔTm
obs, and green indicates
small ΔTm
obs. Experiments were carried out in duplicate; average values are reported.
Figure3. (A)X-raycrystalstructureof4d(carbon=yellow)boundtohumanBRD4(1)(PDBID:3SVG).TheconservedN140residueishighlighted
in green. Black dashedlines represent hydrogenbondsbetween 4d, structured water molecules(red spheres), and interactingresidues (labeled).Image
generated using PyMOL. (B) A schematic representation of the key interactions formed between 4d and human BRD4(1).6766 dx.doi.org/10.1021/jm200640v |J. Med. Chem. 2011, 54, 6761–6770
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ligands that display potencies similar to those of (+)-JQ1 and
I-BET but with lower molecular mass than those of these
compounds.
Identiﬁcation of CREBBP bromodomain inhibitors has so far
provedchallenging,withonlytwostudiesidentifyingsmall-mole-
cule ligands for this bromodomain.
14,15 Therefore, given that
compound 4b shows some selectivity for CREBBP bromodo-
main over other subfamilies, the costructure of 4b bound to the
CREBBPbromodomainwasobtainedat1.80Åresolution(PDB
ID: 3SVH). Compound 4b, which possesses a carboxylic acid
group in place of the secondary alcohol of 4d, binds to the
CREBBPbromodomaininanorientationsimilartothatadopted
by 4d when binding to BRD4(1). The dimethylisoxazole moiety
again acts as a KAc mimic and occupies the KAc-binding pocket.
Likewise,theisoxazoleoxygenatomformsahydrogenbondwith
the amine group of N1168 (equivalent to N140 in BRD4(1),
green, Figure 4A). The isoxazole nitrogen atom also interacts
withthephenolgroupofY1125[equivalenttoY97inBRD4(1)]
via the structured water molecule A. The dihedral angle between
the 3,5-dimethylisoxazole and the phenyl ring of compounds 2,
4b, and 4d diﬀers in the crystal structures obtained. However,
this angle is observed as 50 in the case of 2 [BRD4(1)], 45 in
the case of 4d [BRD4(1)] and 39 in the case of 4b (CREBBP),
which are all similar to the angle of 40 in the predicted lowest
energyconformation(SupportingInformation,FigureS5),suggesting
that these compounds can bind in the KAc-binding pocket
without the introduction of signiﬁcant strain. The oxygen atom
oftheethoxygroupin4bformsahydrogenbondwithstructured
water G, which interacts with the turn-forming residues
1110 1113. Interestingly, this structured water molecule is also
present in BRD4(1), but the orientation of the ethoxy group in
compound 4d is such that it does not form a similar hydrogen
bond, at least within crystals. Residue W81, which plays a key
role in deﬁning the binding site in BRD4(1), is not present in
CREBBP. The equivalent amino acid is L1109, which although
also hydrophobic, is oriented away from the binding site,
providing more space in this region. R1173 provides a basic
rim to the binding pocket, which is not present in BRD4.
Althoughtheseresiduesarenotindirectcontactwiththecarboxylic
acid of 4b, it is possible that a weak electrostatic interaction might
explain,atleastinpart,thepreferentialbindingofthiscompoundto
CREBBP over the BET bromodomains. It should be noted that
C R E B B Pc r y s t a l l i z e da sad i m e r ,w i t has e c o n dm o l e c u l eo f4b
boundatthedimerinterface.Thisphenomenonisthoughttoresult
from the relatively high concentration of 4b used in obtaining the
structureandisunlikelytoberesponsibleforthiscompound’sability
to prevent the CREBBP KAc interaction.
Insummary,wehave discoveredanentirely new chemical class
of bromodomain ligands comprising low-molecular weight
4-phenyl-3,5-dimethylisoxazole derivatives. Using structure-based
approaches, we have demonstrated that the unstable dihydroqui-
nazolinonemoietyoflead1canbereplacedwithasinglearomatic
ring without signiﬁcant loss of aﬃnity. Most of the resultant
4-phenyl-3,5-dimethylisoxazoles are selective ligands for the BET
familyofbromodomains.However,compounds4b dproduceda
marked increase inTm
obs for CREBBP, suggesting that 3,5-dimethyl-
isoxazolesarealsousefulleadsforselectiveinhibitorsofCREBBP-
KAcinteractions,whichhaveprovedelusivetodate.Thecostructures
that we have obtained demonstrate that the 3,5-dimethylisox-
azole moiety acts as a KAc bioisostere in two classes of bromo-
domains, corroborating the binding data and IC50 values pre-
sented. As few chemical classes of small-molecule inhibitors
of bromodomain histone interactions have been described pre-
viously,
15 20 this work represents a signiﬁcant advance in the
SAR of these important proteins.
In conclusion, we have exploited the serendipitous discovery
ofaKAcmimictodevelopanovelclassofcompoundsthatinhibit
bromodomain histone interactions. Crystallographic analysis and
rational design have provided insight into the structural require-
ments for potent, selective BRD4(1) and CREBBP bromodo-
main ligands. These compounds are invaluable leads in the
continuing search for chemical probes of epigenetic targets.
’EXPERIMENTAL SECTION
GeneralExperimental.
1HNMRspectrawererecordedonBruker
DPX400 or DQX400 (400 MHz) or Bruker AVII 500 (500 MHz) using
deuterochloroform (unless indicated otherwise) as a reference for the
internaldeuteriumlock.Thechemicalshiftdataforeachsignalaregiven
as δH in units of parts per million (ppm) relative to tetramethylsilane
Figure4. (A)X-raycrystalstructureof4b(carbon=yellow)boundtothebromodomainofhumanCREBBP(PDBID:3SVH).TheconservedN1168
residue is highlighted in green. Black dashed lines represent hydrogen bonds among 4b, structured water molecules (red spheres), and interacting
residues (labeled). Image generated using PyMOL. (B) Schematic representation of the key interactions formed between 4b and the bromodomain of
human CREBBP.6767 dx.doi.org/10.1021/jm200640v |J. Med. Chem. 2011, 54, 6761–6770
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(TMS) where δH (TMS) = 0.00 ppm. The multiplicity of each signal is
indicated by s (singlet); br s (broad singlet); d (doublet); t (triplet);
q (quartet); dd (doubletofdoublets); ddd(doubletof doubletofdoublets);
or m (multiplet). The number of protons (n) for a given resonance signal is
indicatedbynH.Couplingconstants(J)arequotedinHzandarerecordedto
the nearest 0.1 Hz. Identical proton coupling constants (J) are averaged in
eachspectrumandreportedtothenearest0.1Hz.Thecouplingconstantsare
determined by analysis using Bruker TopSpin software.
13C NMR spectra were recorded on Bruker DQX400 (100 MHz) or
Bruker AVII 500 (125 MHz) spectrometers with broadband proton
decoupling and a internal deuterium lock. The chemical shift data for
each signal are given as δC in units of parts per million (ppm) relative to
tetramethylsilane (TMS) where δC (TMS) = 0.00 ppm.
19F NMR spectra were recorded on Bruker AVII 500 (470 MHz)
using a broadband proton decoupling pulse sequence and deuterium
internal lock. The chemical shift data for each signal are given as δF in
units of parts per million (ppm).
11B NMR spectra were recorded on a Bruker DRX500 (160 MHz).
ThechemicalshiftdataforeachsignalaregivenasδBinunitsofpartsper
million (ppm).
Mass spectra were acquired on a VG platform spectrometer. Electro-
spray ionization spectra were obtained on Micromass LCT Premier and
Bruker MicroTOF spectrometers, operating in positive or negative
mode, from solutions of MeOH. m/z values are reported in Daltons
and followed by their percentage abundance in parentheses.
Melting points were determined using a Koﬂer hot stage microscope
and are uncorrected.
Compound purity foralltested compoundswasdetermined by elemental
analysis, obtained at the Elemental Analysis Service, London Metropolitan
University, London. Elemental analysis was carried out in duplicate; average
values are reported in Supporting Information. For all tested compounds,
experimentally determined hydrogen, carbon, and nitrogen composition was
within (0.4% of the expected value, implying a purity of >95%.
Synthetic Procedures and Characterization for Compounds
3a d, 4a d. 3,5-Dimethyl-4-phenylisoxazole 3a
27. Method A. To a
dry2 5 mLmicrowavevialwere added8(108mg, 532μmol), Pd(OAc)2
(2 mg, 8 μmol), RuPhos (7 mg, 15 μmol), and anhydrous Na2CO3
(106 mg, 1.00 mmol). The vial was sealed and purged with argon (3  
evacuate/fill). Bromobenzene 5 (79 mg, 53 μL, 496 μmol) and degassed
EtOH(2.8mL)wereaddedbysyringe,andthemixturewasheatedat85C
for4h.Themixturewascooledtortandfilteredthroughathinpadofsilica
(eluentCH2Cl2)a n dc o n c e n t r a t e din vacuo. Purification by silica gel column
chromatography(gradientelution,gradient6f30%Et2O/petroleumether)
gave 3a as a colorless oil which crystallized slowly on standing (73 mg,
85%);mp37 38C(lit.42 43C);
27 1HNMR(400MHz,CDCl3)2.29
(s, 3H), 2.42 (s, 3H), 7.24 7.29 (m, 2H), 7.34 7.40 (m, 1H), 7.42 7.48
(m, 2H); m/z (ES
+) 174 ([M + H]
+, 73), 196 ([M + Na]
+, 100), 369
([2M + Na]
+, 19). These data are in good agreement with the literature
values.
27
Method B. To a dry 2 5 mL microwave vial were added PdCl2
(0.5mg,3μmol)andKOAc(98mg,1.0mmol).Thevialwassealedand
purged with argon (3  evacuate/fill). Degassed DMAc (2.5 mL),
bromobenzene 5 (53 μL, 79 mg, 503 μmol), and 3,5-dimethylisoxazole
(74 μL, 73 mg, 752 μmol) were added, and the reaction was heated at
130 C for 27 h. The mixture was filtered through Celite (eluent Et2O),
andthefiltratewaswashedwithwater(40mL)andbrine(40mL),dried
(MgSO4), filtered and concentrated in vacuo. Purification by flash
column chromatography (gradient elution, gradient 3 f 30% Et2O/
petroleum ether) gave 3a as a pale yellow solid (60 mg, 69%).
1 3-(3,5-Dimethylisoxazol-4-yl)phenyl)ethanone 3b
23. Method A.
To a dry 2 5 mL microwave vial were added 8 (108 mg, 532 μmol),
Pd(OAc)2 (2 mg, 8 μmol), RuPhos (7 mg, 15 μmol), and anhydrous
Na2CO3(106mg,1.00mmol).Thevialwassealedandpurgedwithargon
(3  evacuate/fill). 1-(3-Bromophenyl)ethanone 6 (100 mg, 66 μL,
500 μmol) and degassed EtOH (3.8 mL) were added by syringe, and
themixturewasheatedat85Cfor13h.Themixturewascooledtortand
filtered through a thin pad of silica (eluent 25% MeOH/EtOAc) and
concentrated in vacuo. Purification by silica gel column chromatography
(gradientelution,gradient6f50%EtOAc/petroleumether)gave3basa
paleyellow solid (93mg, 86%);mp107 110 C (50% Et2O/40 60 C
petroleum ether);
1H NMR (400 MHz, CDCl3) 2.29 (s, 3H), 2.43 (s,
3H), 2.65 (s, 3H), 7.44 7.49 (m, 1H), 7.53 7.60 (m, 1H), 7.85 7.89
(m,1H),7.93 7.98(m,1H);m/z(ES
+)216([M+H]
+,54),238([M+
Na]
+,100),453([2M+Na]
+,65).Thesedataareingoodagreementwith
the literature values.
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MethodB.Toadry2 5mLmicrowavevialwereaddedPdCl2(0.5mg,
3 μmol) and KOAc (98 mg, 1.0 mmol). The vial was sealed and purged
with argon (3  evacuate/fill). Degassed DMAc (2.5 mL), 1-(3-bromo-
phenyl)ethanone 6 (66 μL, 100 mg, 502 μmol), and 3,5-dimethylisox-
azole(74μL,73mg,752μmol)wereadded,andthereactionwasheated
at 130 C for 20 h. The mixture was filtered through Celite (eluent
EtOAc), and the filtrate was washed with water (2   25 mL) and brine
(25mL),dried(MgSO4),filteredandconcentratedinvacuo.Purification
by flash column chromatography (gradient elution, gradient 6 f 50%
EtOAc/petroleum ether) gave 3b as a pale yellow solid (55 mg, 51%).
4-(3-Ethoxyphenyl)-3,5-dimethylisoxazole 3c. To a dry 2 5m L
microwave vial were added 8 (108 mg, 532 μmol), Pd(OAc)2 (2 mg,
8 μmol), RuPhos (7 mg, 15 μmol), and anhydrous Na2CO3 (106 mg,
1.00 mmol). The vial was sealed and purged with argon (3  evacuate/
fill). Compound 7 in degassed EtOH (178 μM, 2.8 mL, 499 μmol) was
added by syringe, and the mixture was heated at 85 C for 2 h. The
mixture was cooled to rt and filtered through a thin pad of silica (eluent
CH2Cl2) and concentrated in vacuo. Purification by silica gel column
chromatography (gradient elution, gradient 5 f 40% Et2O/petroleum
ether) gave 3c as a pale yellow solid (94 mg, 87%); mp 51 52 C (15%
Et2O/petroleum ether);
1H NMR (400 MHz, CDCl3) 1.44 (t, J =
7.0Hz,3H),2.27(s,3H),2.41(s,3H),4.06(q,J=7.0,2H),6.78(dd,J=
2.4, 1.6 Hz, 1H), 6.82 (ddd, J = 7.7, 1.6, 0.9 Hz, 1H), 6.89 (ddd, J = 8.2,
2.4,0.9Hz,1H),7.33(dd,J=8.2,7.7Hz,1H);HRMSm/z(ES
+)found
[M+Na]
+240.0994, C13H15NNaO2requires M
+240.0995; m/z(ES
+)
218 ([M + H]
+, 47), 240 ([M + Na]
+, 100), 457 ([2M + Na]
+, 99).
(RS)-1-(3-(3,5-Dimethylisoxazol-4-yl)phenyl)ethanol 3d. To a solu-
tionof3b(100mg,465μmol)inanhydrousMeOH(2mL)at0Cwas
added NaBH4 (18 mg, 476 μmol). The mixture was warmed to rt and
stirred for 2 h, then quenched with saturated aqueous NH4Cl (10 mL).
ThesolutionwasextractedwithCH2Cl2(3 10mL),andthecombined
organiclayerswerewashedwithwater(30mL)andbrine(30mL),then
dried(MgSO4),filtered,andconcentratedinvacuo.Purificationbysilica
gel column chromatography (gradient elution, gradient 8 f 70% EtOAc/-
40 60 C petroleum ether) gave 3d as a colorless solid (78 mg, 77%);
mp 72 73 C (40% EtOAc/40 60 C petroleum ether);
1H NMR
(400 MHz, CDCl3) 1.53 (d, J = 6.4 Hz, 3H), 2.26 (s, 3H), 2.30 (br s,
1H), 2.40 (s, 3H), 4.95 (q, J = 6.4 Hz, 1H), 7.13 7.17 (m, 1H),
7.26 7.29(m,1H),7.34 7.44(m,2H);HRMSm/z(ES
+)found[M+
Na]
+ 240.1002, C13H15NNaO3 requires M
+ 240.0995; m/z (ES
+) 218
([M + H]
+, 26), 240 ([M + Na]
+, 81), 457 ([2M + Na]
+, 100).
Ethyl 3-(3,5-dimethylisoxazol-4-yl)-5-ethoxybenzoate 4a. Method
A. To a dry 10 20 mL microwave vial were added 8 (408 mg, 2.01
mmol), 10 (500 mg, 1.83 mmol), Pd(OAc)2 (4 mg, 16 μmol), RuPhos
(26mg,56μmol),andanhydrousNa2CO3(388mg,3.66mmol).Thevial
was sealed and purged with argon (3  evacuate/fill). Degassed EtOH
(10 mL) was added by syringe, and the mixture was heated at 100 Cf o r
48 h. The mixture was cooled to rt and filtered through a thin
pad of silica (eluent CH2Cl2) and concentrated in vacuo. Purification
bysilicagelcolumnchromatography(gradientelution,gradient6f50%
Et2O/petroleum ether) gave 4a as a colorless solid (370 mg, 70%); mp
102 105C(CH2Cl2);
1HNMR(400MHz,CDCl3)1.40(t,J=7.1Hz,
3H), 1.46 (t, J = 7.0 Hz, 3H), 2.28 (s, 3H), 2.42 (s, 3H), 4.11 (q,6768 dx.doi.org/10.1021/jm200640v |J. Med. Chem. 2011, 54, 6761–6770
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J = 7.0 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H), 6.96 (dd, J = 2.3, 1.7 Hz, 1H),
7.52 (dd,J = 1.7, 1.4 Hz, 1H), 7.55 (dd,J = 2.3, 1.4 Hz, 1H); HRMSm/z
(ES
+)found[M+Na]
+312.1204,C16H19NNaO4requiresM
+312.1206;
m/z(ES
+) 290([M +H]
+,29),312([M +Na]
+,50),602([2M+Na]
+,
100).
Method B. To a dry 0.5 2 mL microwave vial were added PdCl2
(0.5mg,3μmol),KOAc(36mg,367μmol),and10(28mg,103μmol).
The vialwas sealed and purged with argon(3  evacuate/fill). Degassed
DMAc (1 mL) and 3,5-dimethylisoxazole (15 μL, 15 mg, 154 μmol)
wereadded,andthereactionwasheatedat130Cfor44h.Themixture
was filtered through Celite (eluent EtOAc), and the filtrate was washed
with water (2   30 mL) and brine (30 mL), dried (MgSO4), and con-
centrated in vacuo. Purification by flash column chromatography
(gradient elution, gradient 5 f 60% EtOAc/petroleum ether) gave 4a
as a colorless solid (25 mg, 44%).
3-(3,5-Dimethylisoxazol-4-yl)-5-ethoxybenzoic acid 4b. To a solu-
tion of 4a (300 mg, 1.04 mmol) in THF (5 mL) were added water
(2.5mL)andLiOH(37mg,1.56mmol),andthemixturewasstirredfor
16 h at rt. NaOH (1 M, 10 mL) was then added, and the mixture was
washedwithEt2O(3 10mL).ThesolutionwasacidifiedtopH2with
HCl (1 M) and extracted with CH2Cl2 (3   40 mL). The combined
organic layers were washed with brine (100 mL), dried (MgSO4),
filtered, and concentrated in vacuo. Repeated recrystallization from
cyclohexane/CHCl3(2:1)gave4basacolorlesscrystallinesolid(225mg,
83%);mp191 193C(cyclohexane/CHCl3,2:1);
1HNMR(500MHz,
CDCl3) 1.48 (t, J = 7.0 Hz, 3H), 2.31 (s, 3H), 2.45 (s, 3H), 4.14 (q, J =
7.0 Hz, 2H), 7.03 7.05 (m, 1H), 7.60 7.63 (m, 2H); HRMS m/z
(ES
+)found[M+Na]
+284.0886,C14H15NNaO4requiresM
+284.0893;
m/z (ES
+) 262 ([M + H]
+, 32), 284 ([M + Na]
+, 100), 545 ([2M +
Na]
+, 75).
1-(3-(3,5-Dimethylisoxazol-4-yl)-5-ethoxyphenyl)ethanone 4c. To
a dry 2 5 mL microwave vial were added 8 (88 mg, 433 μmol), 13
(100 mg, 411 μmol), Pd(OAc)2 (1 mg, 4 μmol), RuPhos (6 mg,
13 μmol), and anhydrous Na2CO3 (87 mg, 821 μmol). The vial was
sealed and purged with argon (3  evacuate/fill). Degassed EtOH
(2.3 mL) was added by syringe, and the mixture was heated at 85 C
for 64 h. The mixture was cooled to rt and filtered through a thin pad of
silica (eluent CH2Cl2) and concentrated in vacuo. Purification by silica
gel column chromatography (gradient elution, gradient 6 f 50%
EtOAc/petroleum ether) gave 4c as a pale yellow solid (71 mg, 67%);
mp 104 106 C (CH2Cl2);
1H NMR (500 MHz, CDCl3) 1.47 (t, J =
7.0 Hz, 3H), 2.29 (s, 3H),2.43 (s, 3H),2.62 (s,3H), 4.13 (q, J= 7.0 Hz,
2H), 6.98 (dd, J = 2.2, 1.5 Hz, 1H), 7.41 (dd, J = 1.5, 1.5 Hz, 1H), 7.46
(dd,J=2.2,1.5Hz,1H);HRMSm/z(ES
+)found[M+Na]
+282.1098,
C15H17NNaO3 requires M
+ 282.1101; m/z (ES
+) 260 ([M + H]
+, 35),
282 ([M + Na]
+, 62), 541 ([2M + Na]
+, 100).
(RS)-1-(3-(3,5-Dimethylisoxazol-4-yl)-5-ethoxyphenyl)ethanol 4d.
To a solution of 4c (30 mg, 123 μmol) in anhydrous MeOH (1 mL)
at 0 C was added NaBH4 (6 mg, 159 μmol). The mixture was warmed
to rt and stirred for 2 h, then quenched with saturated aqueous NH4Cl
(10 mL). The solution was extracted with CH2Cl2 (3   10 mL), and the
combined organic layers were washed with water (30 mL) and brine
(30 mL), then dried (MgSO4), filtered, and concentrated in vacuo.
Purification by silica gel column chromatography (gradient elution,
gradient 10 f 100% EtOAc/40 60 C petroleum ether) gave 4d
as a pale yellow viscous oil (26 mg, 81%);
1H NMR (400 MHz, CDCl3)
1.44 (t,J = 7.0 Hz, 3H),1.52 (d, J = 6.4 Hz, 3H),2.14 (br s, 1H), 2.27 (s,
3H), 2.41 (s, 3H), 4.07 (q, J = 7.0 Hz, 2H), 4.91 (q, J = 6.4 Hz, 1H),
6.66 6.69 (m, 1H), 6.81 6.84 (m, 1H), 6.92 6.95 (m, 1H); HRMS
m/z (ES
+)f o u n d[ M+N a ]
+ 284.1246, C15H15NNaO3 requires
M
+ 284.1257; m/z (ES
+) 262 ([M + H]
+, 21), 284 ([M + Na]
+, 47),
545 ([2M + Na]
+, 100).
Computational Procedures. DockingProcedures forStructure-
Aided Design. Docking of compounds was carried out using the
standard protocol
28 implemented in ICM-Pro 3.6-1 (Molsoft LLC).
The costructure of 2 bound to BRD4(1) (PDB ID: 3SVF) was used to
define the receptor; only water molecules interacting with 2 were
included.
Conformational Analysis of Lead Compounds. Conformational
analysis was performed for the two cocrystallized compounds (4b and
4d) using MacroModel (version 9.8) in Schrodinger Suite 2010 from
Schrodinger LLC. The dihedral angle between the two ring systems was
subjectedtocoordinationscanwith1degreeofincrement.Thechemical
structures from Ligprep were used as the starting structure. The default
optionwasused,includingaforcefieldofOPLS2005,asolventofwater,
andaPRCGminimizationprotocolwithaconvergencegradientof0.05.
The relative energy in kcal/mol of each minimized structure was then
plotted versus the dihedral angle.
Biological Evaluation of Compounds. Protein Expression and
Purification. Proteins were cloned, expressed, and purified as previously
described.
18
Peptides. H4Ac4 peptide (BRD2 and BRD4 assays, H2N-SGRGK-
(Ac)GGK(Ac)GLGK(Ac)-GGAK(Ac)RHRK(Biotin)-COOH) and
H3K56Ac peptide (CREBBP assay, H2N-ALREIRRYQK(Ac)STELLI-
RKLK(Biotin)-COOH) were synthesized by Tufts University Core
Facility.
Thermal Stability Shift Assay. Thermal melting experiments were
carried out using the Mx3005p real-time PCR machine (Agilent) and
employing a protein concentration of 2 μM and an inhibitor concentra-
tion of 100 mM. Buffer conditions were 10 mM HEPES, pH 7.5,
500 mM NaCl and 1:1000 dilution of SyproOrange (Invitrogen, CA).
Theassayanddataevaluationwerecarriedoutasdescribedpreviously.
29
Experiments were performed in duplicate; average values are reported.
AlphaScreen Peptide Displacement Assay. Bromodomain AlphaSc-
reenassayswerecarriedoutaspreviouslydescribed.
18,21Allexperiments
were carried out in duplicate on the same plate. Interexperimental IC50
values generated for individual compounds typically varied over an ∼3-
fold range. However, rank order remained highly consistent between
repeat experiments, with Spearman rank order correlations for 3a d
and4a d>0.90forrepeatsofeachassay.Thus,forthepurposesofSAR,
data in Table 1 is given from a single assay, with intraexperimental
variability expressed as 95% confidence intervals resulting from sigmoi-
dal curve fitting to duplicate data.
Cytotoxicity Assay. HeLa cells were subcultured in DMEM supple-
mented with L-glutamine and 10% fetal calf serum. 20000 cells per well
were seeded into a 96 well plate. After 24 h of incubation at 37 C, the
medium was changed, and compounds were applied at final concentra-
tions of 10, 1, 0.1, and 0.01 μM. The cells were incubated for 24 or 48 h,
after which time the medium was changed, and MTT solution (5 mg/
mL)wasaddedtotheplate.After2hofincubationat37C,themedium
was replaced with 200 μL of DMSO to solubilize the formazan crystals.
After a further 15 min, absorbance was measured at 550 nm using a
spectrophotometer. Experiments were performed in triplicate on the
same plate.
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